E A.I CyberSecurity Scoring
03/05/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for EFOR (formerly Altogen Switzerland) in 2026.
No incidents recorded for EFOR (formerly Altogen Switzerland) in 2026.
No incidents recorded for EFOR (formerly Altogen Switzerland) in 2026.
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use
Latest updates, reports, and threat intel affecting the global network.
The Bluetooth Classic Hands-Free Profile HF role in subsys/bluetooth/host/classic/hfp_hf.c does not release the AT command buffers that are still queued on hf->tx_pending when the RFCOMM DLC goes down. hfp_hf_disconnected() only cancelled the work items and cleared hf->acl, and no other code path ever dequeues those buffers, so each one is permanently lost from the fixed hf_pool (CONFIG_BT_MAX_CONN + 1 buffers, i.e. two in the default configuration). The same function also left BT_HFP_HF_FLAG_CONNECTED set, and hfp_hf_create() wiped the object with memset() as soon as hf->acl was NULL, without checking whether hf->work, hf->slc_work or hf->deferred_work was still pending or running. The remote Audio Gateway peer controls the trigger end to end and needs no application involvement: an unsolicited +BCS: 1 response makes bcs_handle() call bt_hfp_hf_select_codec() and queue an AT+BCS buffer, which cannot be transmitted while BT_HFP_HF_FLAG_RX_ONGOING is set, and an immediately following RFCOMM DISC strands that buffer. Repeating the connect / +BCS / disconnect cycle a couple of times empties hf_pool for good. With the pool exhausted, HFP command sending fails permanently, and because hfp_hf_send_cmd() allocates with K_FOREVER (bt_rfcomm_create_pdu() → bt_conn_create_pdu()) from the Bluetooth RX context — where that timeout is not downgraded to K_NO_WAIT — one further +BCS from the peer parks the Bluetooth RX thread inside net_buf_alloc() with no possible waker, halting all HCI event processing until the device is rebooted. Separately, reusing the HF slot while a work handler was still queued or running allowed memset() to wipe live k_work items out from under the system workqueue, corrupting shared kernel workqueue state. Exploitation requires an established HFP session (for SSP devices L2CAP enforces authentication before the RFCOMM channel is reachable) and a build with CONFIG_BT_HFP_HF enabled.
The user-mode syscall verifier z_vrfy_rtio_cqe_get_mempool_buffer() in subsys/rtio/rtio_syscalls.c validated its two output parameters, buff and buff_len, with K_SYSCALL_MEMORY_READ() rather than K_SYSCALL_MEMORY_WRITE(). Both are pure out-parameters: z_impl_rtio_cqe_get_mempool_buffer() stores the mempool buffer address and its length through them. The distinction is enforced by every architecture validator — arch_buffer_validate() on RISC-V PMP explicitly accepts the global __rom_region/__rodata_region for reads only, and the ARM MPU validators accept P_RO_U_RO and P_RW_U_RO regions for reads only — so a read-validated pointer is not necessarily writable by the calling thread. An unprivileged user-mode thread that has been granted access to an RTIO context (rtio_access_grant()) can invoke the rtio_cqe_get_mempool_buffer() syscall with buff/buff_len pointing at memory it may read but not write, and with a completion-queue entry whose flags field it fully controls (only RTIO_CQE_FLAG_MEMPOOL_BUFFER in flags[7:0] is required; flags[19:8] and flags[31:20] supply the block index and count). The kernel then performs a pointer-sized and a 4-byte store through those addresses while running in supervisor mode. Reaching the store requires CONFIG_USERSPACE together with CONFIG_RTIO_SYS_MEM_BLOCKS, the configuration behind RTIO_DEFINE_WITH_MEMPOOL; without the latter the implementation returns -ENOTSUP and writes nothing. Two outcomes follow. If the target lies in a memory-domain partition declared K_MEM_PARTITION_P_RW_U_RO (privileged read-write, user read-only), the kernel-mode store succeeds and deposits partly attacker-chosen values into memory the memory domain had marked read-only for that thread, bypassing the partition's write protection. If the target lies in globally readable but unwritable memory such as .text/.rodata in flash, the store faults in kernel mode; the fault is delivered to z_fatal_error() and the default k_sys_fatal_error_handler() halts or reboots the device, giving an unprivileged thread a reliable full denial of service. The read-permission check does bound the damage: the address must still be readable by the calling thread, so kernel-private memory cannot be targeted and no confidential data is disclosed. The fix replaces both checks with K_SYSCALL_MEMORY_WRITE(), so a thread lacking write permission is terminated by K_OOPS before the implementation runs; the cqe argument correctly remains read-validated.
IBM Storage TS4500 Library 1.1.1.6 through 1.12.0.3 could allow a remote authenticated attacker to gain unauthorized administrative privileges due to a race condition.
The html_to_markdown expansion module in MISP Modules contains a server-side request forgery (SSRF) vulnerability in its is_safe_url() URL validation function. The BLOCKED_RANGES list used to reject unsafe destination addresses was incomplete, omitting several critical IP address ranges. Specifically, the following ranges were not blocked: 0.0.0.0/8 (unspecified, which routes to loopback on Linux), 100.64.0.0/10 (carrier-grade NAT per RFC 6598), ::/128 (IPv6 unspecified), fc00::/7 (IPv6 Unique Local Addresses), and fe80::/10 (IPv6 link-local). The existing list only covered IPv4 loopback (127.0.0.0/8), RFC 1918 private ranges, IPv4 link-local (169.254.0.0/16), and IPv6 loopback (::1/128). An authenticated user with the ability to create or modify MISP attributes that trigger the html_to_markdown expansion module could supply URLs pointing to these unblocked internal address ranges. Because the module fetches the URL server-side to convert HTML content to Markdown, the request is made from the MISP server's network context. This allows an attacker to probe and read responses from internal services, carrier-grade NAT infrastructure, or link-local endpoints that would otherwise be unreachable from external networks. IPv4-mapped IPv6 forms (e.g., [::ffff:0.0.0.0]) also bypassed the existing checks. The security impact is primarily confidentiality: an attacker can read data served by internal services reachable from the MISP server. The MISP instance itself is not compromised, but it is abused as a proxy to access otherwise restricted network resources.
A weakness has been identified in H3C Magic NX15 V100R017. This affects the function importprofile of the file /api/upload. This manipulation of the argument fileName causes path traversal. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.